Intrahepatic Cholangiocellular Carcinoma

3

Review clinical trials related to Intrahepatic Cholangiocellular Carcinoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Application of Super-Resolution Ultrasound (SRUS) in Liver Tumor

The macroscopic vascular supply of liver tumors varies considerably according to histological subtype, lesion size, and disease stage. Current clinical imaging modalities primarily characterize liver tumors based on their macroscopic vascular perfusion patterns. Conventional color Doppler ultrasonography enables qualitative assessment of tumor vascularity, facilitates the differentiation of benign from malignant hepatic lesions, delineates the anatomical relationship between tumors and major intrahepatic vessels, and detects vascular invasion. Nevertheless, these macroscopic vascular characteristics arise from complex microvascular architectures, including vascular distribution patterns, microvessel density, vessel morphology and tortuosity, blood flow velocity, and flow direction. Despite the critical role of tumor microcirculation in tumor progression and therapeutic response, the heterogeneity of microvascular hemodynamics among different liver tumors remains inadequately characterized. The emergence of Super Resolution Ultrasound Imaging (SRUS) has markedly advanced ultrasound imaging by overcoming the acoustic diffraction limit, enabling visualization of microvessels with diameters as small as approximately 20 μm. Unlike conventional ultrasound techniques, SRUS preserves the inherent advantages of ultrasound, including deep tissue penetration and a large field of view, while achieving an approximately tenfold improvement in spatial resolution. This unique combination effectively bridges the long-standing gap between imaging depth and spatial resolution in vascular imaging. Furthermore, by localizing and tracking individual circulating microbubbles,SRUS enables quantitative assessment of microvascular blood flow velocity over a broad dynamic range without Doppler angle dependence. Consequently, super-resolution ultrasound imaging offers an unprecedented opportunity to characterize and compare the microvascular hemodynamic features of benign and malignant liver lesions, thereby improving the accuracy of preoperative differential diagnosis, tumor staging, therapeutic response assessment, and prognostic evaluation.

Participants needed: 350
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: Eastern Hepatobiliary Surgery HospitalUpdated: Jul 16, 2026
Eligibility criteria

Any gender, 18 years or older; [+2]

During the data collection process, if the participant is unable to cooperate fu... [+7]

Status: Not yet recruiting

Preoperative 3D Magnetic Resonance Elastography for Predicting Surgical Risk in Patients Undergoing Hepatectomy

How to accurately and safely evaluate regional liver function before hepatectomy remains an important unsolved problem in the surgical management of hepatocellular carcinoma (HCC). We plan to develop a non-invasive, functional 3D-MRE-based method for preoperative regional hepatic functional reserve assessment, and to evaluate its ability to predict surgical risk and postoperative liver failure in patients with HCC undergoing hepatectomy.

Participants needed: 150
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: Second Affiliated Hospital of Xi'an Jiaotong UniversityUpdated: Jul 15, 2026
Eligibility criteria

Age 18-80 years [+5]

Contraindication to MRI (e.g., non-MRI-compatible implants, severe claustrophobi... [+7]

Status: Recruiting

Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)

This study will evaluate the efficacy and safety of cryoablation combined with lenvatinib plus Tislelizumab compared with FOLFOX in patients with advanced Intrahepatic Cholangiocarcinoma (ICC) who have progressed after first-line treatment.

Participants needed: 92
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Fudan UniversityUpdated: Apr 6, 2025Locations: 1
Eligibility criteria

Written informed consent obtained. [+9]

History of cardiac disease, including clinically significant gastrointestinal bl... [+16]